Related Experiment Video
Updated: Jul 16, 2025

Rapid Determination of the Thermal Nociceptive Threshold in Diabetic Rats
Published on: May 17, 2012
DDD-028: A potent, neuroprotective, non-opioid compound for the treatment of diabetic neuropathy
Laura Micheli1, Jagan Rajamoni2, Lorenzo Di Cesare Mannelli1
1Department of Neuroscience, Psychology, Drug Research and Child Health, NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Abstract:
Diabetic neuropathy (DN) is a painful, chronic ailment that affects a large segment of diabetic population worldwide. Current medications such as pregabalin or duloxetine treat only the pain symptom associated with DN, but not the underlying nerve damage. DDD-028 (1) is a small molecule that displays potent pain-relieving activity in streptozotocin (STZ)-induced rodent model of DN. Combined with other studies indicating that DDD-028 suppresses astrogliosis and nerve damage induced by the anti-cancer drug, paclitaxel, the present study suggests that DDD-028 would be useful as a disease modifying therapeutic in the treatment of DN. The 3-dimensional structure of DDD-028 was confirmed by single crystal X-ray crystallography.

